Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
1998-09-01
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
A61K 3159
Patent
active
058011641
ABSTRACT:
Methods of treating osteoporosis prophylactically or therapeutically are disclosed. The method of treating osteoporosis includes administering to a patient suffering therefrom an effective amount to treat the osteoporosis of novel 1.alpha.-hydroxyvitamin D.sub.4 and novel analogues 1,25-dihydroxyvitamin D.sub.4 and 1,24-dihydroxyvitamin D.sub.4, the aforementioned compounds having lower toxicity as measured by an LD.sub.50 test in rats when compared to a corresponding vitamin D.sub.3 compound. The method of administering the compound is substantially without occurrence of hypercalcemia.
REFERENCES:
patent: 2383446 (1945-06-01), Calcott et al.
patent: 3697559 (1972-10-01), DeLuca et al.
patent: 3741996 (1973-06-01), DeLuca et al.
patent: 4195027 (1980-03-01), DeLuca et al.
patent: 4202829 (1980-05-01), DeLuca et al.
patent: 4241051 (1980-12-01), Christie et al.
patent: 4260549 (1981-04-01), DeLuca et al.
patent: 4362710 (1982-12-01), Watanabe
patent: 4555364 (1985-11-01), DeLuca et al.
patent: 4661294 (1987-04-01), Holick et al.
patent: 4689180 (1987-08-01), DeLuca et al.
patent: 4866048 (1989-09-01), Calverley et al.
patent: 5157135 (1992-10-01), Tsuji et al.
Martin, D. L. and DeLuca, H. F. Arch. Biochem, Biophys., 134:139-148 (1969).
Sorenson, O.H. et al, 7 Clin. Endocr. (1977) Supp. 169S-175S.
E. Braunwald et al., Harrison's Principles of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism," Chapter 335, McGraw-Hill, New York, 1987, pp. 1860-1865.
Grab, W., Z. Physiol. Chem., 243:63-89 (1936).
McDonald, F. G., J. Biol. Chem., 114:IVX (1936).
Windaus, A. and Trautmann, G., Z. Physiol. Chem., 247:185-188 (1937).
DeLuca et al., Arch. Biochem, Biophys., 124:122-128 (1968).
Merck Index, S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930.
Barton et al., JCS Perkin I, 1976, 821-826.
Paaren et al., J. Org. Chem., 1980, 45:3253.
Wientroub, S. et al., "The Dichotomy in the Effects of 1,25 dihydroxy vitamin D.sub.3 and 24,25 dihydroxy vitamin D.sub.3 on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in vitamin D-Deficient Rats," Calcif, Tissue Int. (1987) 40:166-172.
Sjoden, G. et al., Proc. Soc. Experimental Biol. Med., 178:432-436 (1985).
Strugnell et al., Biochem. Pharm. vol. 40:333-341 (1990).
Martin and DeLuca, Am. J. Physiol. 216:1352-1359.
Kocienski, P. J., Lythgoe, B. and Ruston, S., J.C.S. Perkins I, 1290-1293 (1979).
Tsuji, M. et al., Bull. Chem. Soc. Jpn., vol. 63, No. 8, 2233-2238 (1990).
Crump, D. R., Williams, D. H. and Pelc, B., J.C.S. Perkins Trans. I, 2731-2733 (1973).
Chemical Abstracts, vol. 113, No. 1, 2 Jul. 1990, Columbus, Ohio, US; abstract No. 6683y, Y. Tachibana, `Preparation of 1beta-hydroxyvitamin D.sub.2 and D.sub.3,` p. 6688; col. 2; *abstract* & JP-A-02 011 563 (Nisshin Flour Milling Co.).
Chemistry Letters, No. 8, Aug. 1985, Tokyo, JP, pp. 1131-1132, H. Nemeto et al., `A stereoselective synthesis of 1 alpha-hydroxy-vitamin D.sub.3 `, *the whole document*.
Bishop Charles W.
Knutson Joyce C.
Moriarty Robert M.
Badio Barbara
Bone Care International, Inc.
Dees Jos,e G.
Welch Teresa J.
LandOfFree
Methods of treating osteoporosis prophylactically or therapeutic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating osteoporosis prophylactically or therapeutic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating osteoporosis prophylactically or therapeutic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-270407